# Aspira Pathlab (NSE: ASPIRA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ASPIRA · Pivot · prices to 19 Oct 2026

With a market capitalisation of ₹125 Cr, it ranks 2539th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Diagnostics & Research.

Its return on equity was 27.9% in FY25. In Q1 FY26, the quarter ended 30 Jun 2025, revenue was ₹5 Cr (+13.1% year on year) and net profit ₹0 Cr, on a consolidated basis. Promoters held 46.58% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹125 Cr |
| ROE | 27.9% (FY25) |
| ROCE | 16.0% (FY25) |
| Debt to equity | 0 |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY26 | ₹5 Cr | +13.1% | ₹0 Cr | — | ₹0.41 |
| Q4 FY25 | ₹6 Cr | — | ₹1 Cr | — | ₹0.66 |
| Q3 FY25 | ₹5 Cr | — | ₹0 Cr | — | ₹0.30 |
| Q2 FY25 | ₹6 Cr | — | ₹1 Cr | — | ₹0.96 |
| Q1 FY25 | ₹5 Cr | — | −₹0 Cr | — | ₹0.05 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹22 Cr | ₹2 Cr |
| FY24 | ₹13 Cr | −₹3 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 46.58%
- Non-institutions: 53.42%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Par Drugs And Chemicals](https://app.pivotnow.in/stock/PAR) | ₹105.25 | ₹130 Cr | 9.9 | — |
| [Parnax Lab](https://app.pivotnow.in/stock/PARNAXLAB) | ₹108.95 | ₹125 Cr | 10.6 | — |
| [Krebs Biochemicals and Industries](https://app.pivotnow.in/stock/KREBSBIO) | ₹57.16 | ₹123 Cr | — | — |
| [Makers Labs](https://app.pivotnow.in/stock/MAKERSL) | ₹209.00 | ₹123 Cr | 52.5 | — |
| [Godavari Drugs](https://app.pivotnow.in/stock/GODAVARI) | — | ₹120 Cr | — | — |
| [BALAXI PHARMACEUTICALS](https://app.pivotnow.in/stock/BALAXI) | ₹21.72 | ₹120 Cr | 83.5 | — |

## Questions and answers

### What is the market cap of Aspira Pathlab?

Aspira Pathlab's market capitalisation is ₹125 Cr (₹125 Cr) at the 19 Oct 2026 close, ranking 2539th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Aspira Pathlab?

Return on equity was 27.9% in FY25 and return on capital employed was 16.0% in FY25 (consolidated figures).

### Is Aspira Pathlab a debt-free company?

Aspira Pathlab is close to debt-free: its debt-to-equity ratio was 0 in FY25.

### What were Aspira Pathlab's latest quarterly results?

For Q1 FY26 (quarter ended 30 Jun 2025), Aspira Pathlab reported revenue of ₹5 Cr, +13.1% year on year, and net profit of ₹0 Cr.

### What is the shareholding pattern of Aspira Pathlab?

As of 30 Jun 2026: promoters 46.58%, non-institutions 53.42%.

### Who are Aspira Pathlab's competitors?

The listed Pharma & Healthcare companies closest to Aspira Pathlab by market cap are Par Drugs And Chemicals, Parnax Lab, Krebs Biochemicals and Industries, Makers Labs, Godavari Drugs and BALAXI PHARMACEUTICALS.

### Is Aspira Pathlab a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Aspira Pathlab's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ASPIRA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.